Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 33
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Zevalin and BEAM High-Dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin’s Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Approved-not yet active
18 to 65
Other
Sor451107ctil
NCT00463463
2.
Zevalin-Beam for Aggressive Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 65
Other
SHEBA-07-4466-AN-CTIL
NCT00491491
Last Modified:
8/8/2007
 
First Published:
3/1/2001
3.
Phase I/II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab With and Without Filgrastim (G-CSF) and Interleukin-11 in Patients With Relapsed or Refractory Low-Grade or Follicular CD20+ Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI
MAYO-MC998C
NCI-312, NCT00012298
4.
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 to 70
Other
ID01-233
NCT00048737
Last Modified:
11/22/2006
 
First Published:
11/3/2006
5.
Phase I/II Study of Rituximab, Fludarabine, and Cyclophosphamide Followed by Radioimmunotherapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed Indolent, Mantle Cell, or Transformed CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
51 to 75
Other
KRDI-TUM-R-F-015-V-0030-I
EU-20633, NCT00397800
Last Modified:
4/12/2007
 
First Published:
3/24/2003
6.
Phase II Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Patients Age 60 and Over With Previously Untreated Diffuse Large B-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Active
60 and over
NCI
MSKCC-02090
NCT00058422
Last Modified:
9/10/2008
 
First Published:
9/24/2003
7.
Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone and Radiotherapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Aggressive High-Risk Stage I or IE or Non-Bulky Stage II or IIE CD20-Positive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 18
NCI
SWOG-S0313
S0313, NCT00070018
Last Modified:
7/18/2007
 
First Published:
11/20/2003
8.
Phase II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
BIDMC-2003P-000182
NCT00073957
Last Modified:
9/10/2008
 
First Published:
7/23/2004
9.
Phase II Study of Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, and Vincristine Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Stage I or II CD20-Positive Diffuse Large Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
ECOG-E3402
E3402, NCT00088881
Last Modified:
7/27/2007
 
First Published:
4/7/2005
10.
Phase II Study of Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan as First-Line Treatment in Patients With Indolent Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 18
Other, Pharmaceutical / Industry
BIDMC-2004P-000044
NCT00110149
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute